These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 11515785)

  • 1. Immunolocalization of FAS and FAS ligand in inflammatory myopathies.
    De Bleecker JL; Meire VI; Van Walleghem IE; Groessens IM; Schröder JM
    Acta Neuropathol; 2001 Jun; 101(6):572-8. PubMed ID: 11515785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fas and Fas ligand interaction induces apoptosis in inflammatory myopathies: CD4+ T cells cause muscle cell injury directly in polymyositis.
    Sugiura T; Murakawa Y; Nagai A; Kondo M; Kobayashi S
    Arthritis Rheum; 1999 Feb; 42(2):291-8. PubMed ID: 10025923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dual role for HSP90 and HSP70 in the inflammatory myopathies: from muscle fiber protection to active invasion by macrophages.
    De Paepe B; Creus KK; Martin JJ; Weis J; De Bleecker JL
    Ann N Y Acad Sci; 2009 Sep; 1173():463-9. PubMed ID: 19758187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-1 expression in inflammatory myopathies: evidence of marked immunoreactivity in sarcoid granulomas and muscle fibres showing ischaemic and regenerative changes.
    Authier FJ; Mhiri C; Chazaud B; Christov C; Cherin P; Barlovatz-Meimon G; Gherardi RK
    Neuropathol Appl Neurobiol; 1997 Apr; 23(2):132-40. PubMed ID: 9160898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic mechanisms in inflammatory myopathies. Co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells.
    Behrens L; Bender A; Johnson MA; Hohlfeld R
    Brain; 1997 Jun; 120 ( Pt 6)():929-38. PubMed ID: 9217678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies.
    Choi YC; Dalakas MC
    Neurology; 2000 Jan; 54(1):65-71. PubMed ID: 10636127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis.
    Sallum AM; Kiss MH; Silva CA; Wakamatsu A; Vianna MA; Sachetti S; Marie SK
    Autoimmun Rev; 2006 Feb; 5(2):93-100. PubMed ID: 16431335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies.
    Murata K; Dalakas MC
    Am J Pathol; 1999 Aug; 155(2):453-60. PubMed ID: 10433938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pathogenesis of primary inflammatory myopathies].
    Benveniste O; Squier W; Boyer O; Hilton-Jones D; Herson S
    Presse Med; 2004 Nov; 33(20):1444-50. PubMed ID: 15611679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The inhibition of apoptosis in myositis and in normal muscle cells.
    Nagaraju K; Casciola-Rosen L; Rosen A; Thompson C; Loeffler L; Parker T; Danning C; Rochon PJ; Gillespie J; Plotz P
    J Immunol; 2000 May; 164(10):5459-65. PubMed ID: 10799913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet-endothelial cell adhesion molecule-1 and CD146: soluble levels and in situ expression of cellular adhesion molecules implicated in the cohesion of endothelial cells in idiopathic inflammatory myopathies.
    Figarella-Branger D; Schleinitz N; Boutière-Albanèse B; Camoin L; Bardin N; Guis S; Pouget J; Cognet C; Pellissier JF; Dignat-George F
    J Rheumatol; 2006 Aug; 33(8):1623-30. PubMed ID: 16881117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Major histocompatibility complex class I and II expression in idiopathic inflammatory myopathy.
    Das L; Blumbergs PC; Manavis J; Limaye VS
    Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):539-42. PubMed ID: 23343957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies.
    De Bleecker JL; Meire VI; Declercq W; Van Aken EH
    Neuromuscul Disord; 1999 Jun; 9(4):239-46. PubMed ID: 10399751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemokine profile of different inflammatory myopathies reflects humoral versus cytotoxic immune responses.
    De Paepe B; Creus KK; De Bleecker JL
    Ann N Y Acad Sci; 2007 Aug; 1109():441-53. PubMed ID: 17785333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of chemokines in inflammatory myopathies.
    De Bleecker JL; De Paepe B; Vanwalleghem IE; Schröder JM
    Neurology; 2002 Jun; 58(12):1779-85. PubMed ID: 12084877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Polymyositis, dermatomyositis and inclusion body myositis, nosological aspects].
    Eymard B
    Presse Med; 2003 Oct; 32(35):1656-67. PubMed ID: 14631270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major histocompatibility complex class I expression can be used as a diagnostic tool to differentiate idiopathic inflammatory myopathies from dystrophies.
    Sundaram C; Uppin MS; Meena AK
    Neurol India; 2008; 56(3):363-7. PubMed ID: 18974565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Bcl-2 in inclusion body myositis.
    Fyhr IM; Lindberg C; Oldfors A
    Acta Neurol Scand; 2002 May; 105(5):403-7. PubMed ID: 11982494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of Fas/Fas ligand in inclusion body myositis.
    Fyhr IM; Oldfors A
    Ann Neurol; 1998 Jan; 43(1):127-30. PubMed ID: 9450780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Signal transducer and activator of transcription 1 in human muscle: implications in inflammatory myopathies.
    Illa I; Gallardo E; Gimeno R; Serrano C; Ferrer I; Juárez C
    Am J Pathol; 1997 Jul; 151(1):81-8. PubMed ID: 9212734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.